Pfizer Stock News

Document may include ban on wildlife markets and new virus detection initiatives The European Union is planning to start negotiations on a new pandemic prevention initiative that could introduce a gradual ban on wildlife markets and rewards for countries that report new viruses or variants, according to an unnamed EU official who spoke to Reuters. A meeting will take place on Wednesday for initial talks, and officials are aiming to have produced a first draft of the agreement by August. The upcoming discussions will require the presence of delegates from six major countries in the main regions of the world, which include Japan, Brazil, Egypt, Thailand, South Africa, and the EU, which will be represented by a delegate from the Netherlands. Among the preventive measures that could be proposed during the negotiations is a gradual shutdown of wildlife markets, since the most widely accepted theory suggests the current Covid-19 pandemic began after the SARS-CoV-2 virus was transmitted from an animal to humans at a Chinese wet market.

To get your day started, here are some stories.Â

CEO Albert Bourla says final sales for COVID-19 antiviral Paxlovid could be "way bigger" than forecasts.

The company predicts it will earn as much as $102 billion in 2022, half of it due to Covid-19 vaccine and treatment US pharmaceutical company Pfizer has predicted that it will

In 2021, Pfizer''s annual profits were more than double what they were in 2020. The company brought in $22 billion in profits in 2020.

Pfizer forecast 2022 sales and profit that fell short of Wall Street estimates, as projected revenue from its Covid-19 vaccine and recently cleared oral therapy disappointed investors.

PFE earnings call for the period ending December 31, 2021.

Chief Executive Albert Bourla says 2021 was a ''watershed year'' for drugmaker, with its efforts during the pandemic ''fundamentally changed our company forever''

The post Pfizer CEO says chances are ‘very high’ FDA will approve low-dose Covid shots for kids under 5 appeared on BitcoinEthereumNews.com . Pfizer CEO Albert Bourla on Tuesday said he believes the Food and Drug Administration will authorize the company’s Covid vaccine for children under 5 years old under a fast-track process…

Investors sold shares of Pfizer, Moderna and Novavax after the US pharma giant made sales forecasts for its coronavirus and pill that fell short of market expectations.

The Mandaluyong City local government formally launched the COVID-19 vaccination of children, 5-11 years old, on Tuesday, Feb. 8. (Photo from Mayor Menchie Abalos Facebook) Mandaluyong Mayor Menchie Abalos led in welcoming officials from different national agencies in support of the governments campaign to vaccinate and protect Filipino children from COVID-19. Present were Inter-agency Task Force for the Management of Emerging Infectious Diseases (IATF-EID) chairman and Department of Health (DOH) Secretary Francisco Duque III, National Task Force Chief Implementer Secretary Carlito Galvez Jr., Department of Tourism (DOT) Secretary Bernadette Romulo-Puyat, Department of the Interior and Local Government (DILG) Secretary Eduardo Año, Department of Education (DepEd) Secretary Leonor Briones, Metropolitan Manila Development Authority (MMDA) General Manager Atty. Romando Artes, and Department of Social Welfare and Development (DSWD) Secretary Rolando Bautista. Abalos said the local government unit (LGU) has two vaccination sites specifically designated for the inoculation of children aged 5-11 years old.

Pfizer reported a total of $36.78 billion in global direct sales and alliance revenue from its two-dose COVID-19 vaccine in 2021 and intends to top that incredible amount of revenue this year.

Heidelberg, Germany, Feb. 08, 2022 (GLOBE NEWSWIRE) -- AGC Biologics , a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced an expanded partnership to supply more plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine at the company''s Heidelberg facility. According to a recent news release from Pfizer and BioNTech , the companies have started to develop an Omicron-based COVID-19 vaccine with first batches expected to be ready for delivery by end of March 2022. "We are proud to continue to support BioNTech and supply them with pDNA materials for their vaccine production, as a part of the fight against new pandemic variants," said AGC Biologics Chief Executive Officer, Patricio Massera. "Our pDNA services … Full story available on Benzinga.com

BioNTech had a rough Tuesday with shares closing down 7.6%.

Pfizer forecast more than $50 billion in 2022 sales for its COVID-19 vaccine and therapeutic on Tuesday as the pharmaceutical giant reported a more than doubling of annual profits on strong sales of